During the 2022 GCSG US conference in San Antonio, 65 attendees participated in our Direct-to-Patient (DtP) survey. While 2/3rd’s of the respondents represented pharmaceutical companies / sponsors, there is also a strong mix of input from service providers. Over 50% of participants also had experience with DtP. Though a need for technology improvements was noted, our industry’s adoption of patient centric services like DTP continues to boost the growth of decentralized trials.
Direct-to-Patient Survey Results Summary
Health Care, Innovation, Supply Chain
Related Articles
-
18 November 2022 The Exponential Growth of De... -
18 September 2020 GCSG 2020 Global Virtual Con... -
5 October 2022 Guy Disney - European Knowle...
-
18 November 2022 EU Clinical Trial Regulation...